

# Umesh Mahantshetty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1624776/publications.pdf>

Version: 2024-02-01

122  
papers

4,632  
citations

126708

33  
h-index

110170

64  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3520  
citing authors

#	ARTICLE	IF	CITATIONS
1	Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. <i>Radiotherapy and Oncology</i> , 2016, 120, 428-433.	0.3	527
2	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 48-60.	0.9	415
3	Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1548-1555.	0.8	325
4	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 404-416.	0.3	241
5	Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 120, 412-419.	0.3	198
6	Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1234-1242.	0.8	178
7	Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 118, 160-166.	0.3	153
8	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 919-936.	1.4	127
9	Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix. <i>JAMA Oncology</i> , 2018, 4, 506.	3.4	116
10	Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 88-95.	0.4	106
11	The management of locally advanced cervical cancer. <i>Current Opinion in Oncology</i> , 2018, 30, 323-329.	1.1	82
12	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1088-1098.	0.4	77
13	Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3682-3692.	0.8	70
14	Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 431-439.	0.3	69
15	Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 895-902.	0.4	62
16	Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 608-617.	0.4	57
17	Predictors of Grade 3 or Higher Late Bowel Toxicity in Patients Undergoing Pelvic Radiation for Cervical Cancer: Results From a Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 630-635.	0.4	56
18	Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 423-430.	0.3	54

#	ARTICLE	IF	CITATIONS
19	Gynecological cancers: A summary of published Indian data. South Asian Journal of Cancer, 2016, 05, 112-120.	0.2	53
20	Trans-abdominal ultrasound (US) and magnetic resonance imaging (MRI) correlation for conformal intracavitary brachytherapy in carcinoma of the uterine cervix. Radiotherapy and Oncology, 2012, 102, 130-134.	0.3	50
21	Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting. International Journal of Radiation Oncology Biology Physics, 2018, 101, 201-210.	0.4	47
22	IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer. Radiotherapy and Oncology, 2021, 160, 273-284.	0.3	46
23	Locally advanced cervical cancer: A study of 5-year outcomes. Indian Journal of Cancer, 2018, 55, 45.	0.2	43
24	A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE). Radiotherapy and Oncology, 2016, 120, 404-411.	0.3	42
25	Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiotherapy and Oncology, 2019, 134, 185-190.	0.3	41
26	Comparison of 2 Contouring Methods of Bone Marrow on CT and Correlation With Hematological Toxicities in Non-“Bone Marrow” Sparing Pelvic Intensity-Modulated Radiotherapy With Concurrent Cisplatin for Cervical Cancer. International Journal of Gynecological Cancer, 2012, 22, 1427-1434.	1.2	39
27	Treatment and outcome in cancer cervix patients treated between 1979 and 1994: A single institutional experience. Journal of Cancer Research and Therapeutics, 2013, 9, 672.	0.3	39
28	Clinical trials in low and middle-income countries –“ Successes and challenges. Gynecologic Oncology Reports, 2017, 19, 5-9.	0.3	39
29	Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. International Journal of Radiation Oncology Biology Physics, 2019, 103, 887-894.	0.4	39
30	Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiotherapy and Oncology, 2020, 145, 71-80.	0.3	38
31	Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix. Brachytherapy, 2014, 13, 548-553.	0.2	36
32	Template-based high-dose-rate interstitial brachytherapy in gynecologic cancers: A single institutional experience. Brachytherapy, 2014, 13, 337-342.	0.2	36
33	Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome. Radiotherapy and Oncology, 2019, 141, 123-129.	0.3	35
34	Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE). International Journal of Radiation Oncology Biology Physics, 2015, 93, 788-796.	0.4	34
35	Reporting and Validation of Gynaecological Groupe Europeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) Brachytherapy Recommendations for MR Image-Based Dose Volume Parameters and Clinical Outcome With High Dose-Rate Brachytherapy in Cervical Cancers. International Journal of Gynecological Cancer, 2011, 21, 1110-1116.	1.2	33
36	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 158, 312-320.	0.3	33

#	ARTICLE	IF	CITATIONS
37	A Prospective Comparison of Computed Tomography with Transrectal Ultrasonography Assistance and Magnetic Resonance Imaging-Based Target-Volume Definition During Image Guided Adaptive Brachytherapy for Cervical Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1448-1456.	0.4	32
38	Indian Brachytherapy Society Guidelines for radiotherapeutic management of cervical cancer with special emphasis on high-dose-rate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 293-306.	0.4	32
39	Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 311-327.	1.0	32
40	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 688-700.	0.4	31
41	Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 60-66.	0.4	30
42	Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 440-448.	0.3	30
43	Uncertainties of deformable image registration for dose accumulation of high-dose regions in bladder and rectum in locally advanced cervical cancer. <i>Brachytherapy</i> , 2015, 14, 953-962.	0.2	29
44	Human papillomavirus (HPV) genome status & cervical cancer outcome - A retrospective study. <i>Indian Journal of Medical Research</i> , 2015, 142, 525.	0.4	29
45	Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 325-330.	0.3	27
46	Brachytherapy in India – a long road ahead. <i>Journal of Contemporary Brachytherapy</i> , 2014, 3, 331-335.	0.4	24
47	Late rectal toxicity after image-based high-dose-rate interstitial brachytherapy for postoperative recurrent and/or residual cervical cancers: EQD2 predictors for Grade II toxicity. <i>Brachytherapy</i> , 2015, 14, 881-888.	0.2	24
48	Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 168-177.	0.4	24
49	Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 449-455.	0.3	23
50	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 300-308.	0.3	23
51	Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. <i>Clinical Biochemistry</i> , 2016, 49, 79-84.	0.8	22
52	Education and training for image-guided adaptive brachytherapy for cervix cancer – The (GEC)-ESTRO/EMBRACE perspective. <i>Brachytherapy</i> , 2020, 19, 827-836.	0.2	22
53	Clinical outcome of high-dose-rate interstitial brachytherapy in vulvar cancer: A single institutional experience. <i>Brachytherapy</i> , 2017, 16, 153-160.	0.2	21
54	Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 400-413.	0.4	20

#	ARTICLE	IF	CITATIONS
55	Radiation Oncology in India: Challenges and Opportunities. <i>Seminars in Radiation Oncology</i> , 2017, 27, 158-163.	1.0	19
56	Income generated by women treated with magnetic resonance imaging-based brachytherapy: A simulation study evaluating the macroeconomic benefits of implementing a high-end technology in a public sector healthcare setting. <i>Brachytherapy</i> , 2017, 16, 981-987.	0.2	17
57	Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study. <i>Gynecologic Oncology</i> , 2018, 148, 299-304.	0.6	17
58	National Cancer Grid of India Consensus Guidelines on the Management of Cervical Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-15.	0.5	17
59	Clinical Outcome of Early-Stage Endometroid Adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1446-1452.	1.2	16
60	Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 161-168.	0.4	16
61	MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 310-319.	0.4	16
62	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 161-173.	0.4	16
63	Use of bladder dose points for assessment of the spatial dose distribution in the posterior bladder wall in cervical cancer brachytherapy and the impact of applicator position. <i>Brachytherapy</i> , 2015, 14, 252-259.	0.2	15
64	Predictors of late bowel toxicity using three different methods of contouring in patients undergoing post-operative radiation for cervical cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150054.	1.0	15
65	Meeting the Global Need for Radiation Therapy in Cervical Cancer – An Overview. <i>Seminars in Radiation Oncology</i> , 2020, 30, 348-354.	1.0	15
66	FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1248-1256.	0.4	15
67	Image Guided Brachytherapy in Cervical Cancer: A Comparison between Intracavitary and Combined Intracavitary/Interstitial Brachytherapy in Regard to Doses to HR CTV, OARs and Late Morbidity - Early Results from the Embrace Study in 999 Patients. <i>Brachytherapy</i> , 2016, 15, S21.	0.2	14
68	Dose-volume correlation of cumulative vaginal doses and late toxicity after adjuvant external radiation and brachytherapy for cervical cancer. <i>Brachytherapy</i> , 2017, 16, 855-861.	0.2	14
69	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 681-693.	0.4	14
70	Patterns of cervical cancer brachytherapy in India: results of an online survey supported by the Indian Brachytherapy Society. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 527-533.	0.4	13
71	Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 826-834.	0.4	13
72	Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin. <i>British Journal of Radiology</i> , 2018, 91, 20180005.	1.0	12

#	ARTICLE	IF	CITATIONS
73	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 163, 150-158.	0.3	12
74	Setup error analysis in helical tomotherapy based image-guided radiation therapy treatments. <i>Journal of Medical Physics</i> , 2015, 40, 233.	0.1	12
75	Principles of radiation therapy in low-resource and well-developed settings, with particular reference to cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S153-8.	1.0	11
76	Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1179.	1.3	11
77	Treatment planning of epithelial ovarian cancers using helical tomotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2009, 10, 96-105.	0.8	10
78	Optimal bladder filling during high-dose-rate intracavitary brachytherapy for cervical cancer: a dosimetric study. <i>Journal of Contemporary Brachytherapy</i> , 2017, 2, 112-117.	0.4	10
79	Histopathological risk scoring system as a tool for predicting lymph nodal metastasis in penile squamous cell carcinoma. <i>Pathology</i> , 2019, 51, 696-704.	0.3	10
80	Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis. <i>Ecancermedicalsecience</i> , 2019, 13, 957.	0.6	10
81	A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer. <i>Indian Journal of Cancer</i> , 2018, 55, 327.	0.2	10
82	Brachytherapy in head and neck malignancies: Indian Brachytherapy Society (IBS) recommendations and guidelines. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 501-511.	0.4	10
83	Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 382-387.	0.8	9
84	Dose optimization in gynecological 3D image based interstitial brachytherapy using martinez universal perineal interstitial template (MUPIT) -an institutional experience. <i>Journal of Medical Physics</i> , 2014, 39, 197.	0.1	9
85	Utilization of a Web-Based Conferencing Platform to Improve Global Radiation Oncology Education and Quality—Proof of Principle Through Implementation in India. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 276-280.	0.4	8
86	Somatic Variations in Cervical Cancers in Indian Patients. <i>PLoS ONE</i> , 2016, 11, e0165878.	1.1	7
87	Additional rectal and sigmoid mucosal points and doses in high dose rate intracavitary brachytherapy for carcinoma cervix: A dosimetric study. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 298.	0.3	7
88	Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 379-389.	0.4	7
89	Consensus meeting and update on existing guidelines for management of cervical cancer with special emphasis on the practice in developing countries, including India: The expert panel at the 8 th annual women's cancer initiative Tata Memorial Hospital Conference 2010-11. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2012, 33, 216-220.	0.1	6
90	Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 211-217.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Complications of intracavitary brachytherapy for gynecologic cancers and their management: A comprehensive review. <i>Brachytherapy</i> , 2021, 20, 984-994.	0.2	6
92	Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. <i>Radiotherapy and Oncology</i> , 2021, 157, 24-31.	0.3	6
93	Effect of p53 codon 72 polymorphism on the survival outcome in advanced stage cervical cancer patients in India. <i>Indian Journal of Medical Research</i> , 2016, 144, 359.	0.4	6
94	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1177-1189.	0.4	6
95	Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience. <i>Gynecologic Oncology</i> , 2020, 159, 359-364.	0.6	5
96	Quality of life in long term survivors of cervical cancer: A cross sectional study. <i>Indian Journal of Cancer</i> , 2021, 58, 171-178.	0.2	4
97	Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial. <i>Brachytherapy</i> , 2021, 20, 1146-1155.	0.2	4
98	Outcomes of locally advanced cervical cancer presenting with obstructive uropathy: An institutional audit. <i>Indian Journal of Cancer</i> , 2020, 57, 416-422.	0.2	4
99	Internal target volume for post-hysterectomy vaginal recurrences of cervical cancers during image-guided radiotherapy. <i>British Journal of Radiology</i> , 2015, 88, 20140783.	1.0	3
100	Cardiac metastasis in cervical cancer. <i>BJR   case Reports</i> , 2016, 2, 20150300.	0.1	3
101	Cancer cervix: Establishing an evidence-based strategy, an experience of a tertiary care centre in India. <i>Current Problems in Cancer</i> , 2018, 42, 137-147.	1.0	3
102	Brachytherapy in India: Learning from the past and looking into the future. <i>Brachytherapy</i> , 2020, 19, 861-873.	0.2	3
103	Quantitative and qualitative application of clinical drawings for image-guided brachytherapy in cervical cancer patients. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 512-518.	0.4	3
104	Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials. <i>EClinicalMedicine</i> , 2022, 47, 101390.	3.2	3
105	Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. <i>BMJ Open</i> , 2022, 12, e055765.	0.8	3
106	Validation and applicability of para-aortic lymph nodal contouring atlas in cervical cancer. <i>Radiotherapy and Oncology</i> , 2021, 165, 32-36.	0.3	2
107	Patterns of relapse after adjuvant (chemo)radiation for cervical cancer in a phase III clinical trial (PARCER): an evaluation of updated NRG Oncology /RTOG target delineation guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	2
108	Dosimetric impact of target definition in brachytherapy for cervical cancer – Computed tomography and trans rectal ultrasound versus magnetic resonance imaging. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 21, 126-133.	1.2	2

#	ARTICLE	IF	CITATIONS
109	8th Annual Conference of Indian Brachytherapy Society 2018 (IBSCON 2018) Proceedings. Journal of Contemporary Brachytherapy, 2018, 10, 385-395.	0.4	1
110	9th ANNUAL CONFERENCE OF INDIAN BRACHYTHERAPY SOCIETY 2019 (IBSCON 2019) PROCEEDINGS. Journal of Contemporary Brachytherapy, 2019, 11, 489-503.	0.4	1
111	Long term results of a prospective study of internal mammary chain (IMC) brachytherapy.. Journal of Clinical Oncology, 2015, 33, e12061-e12061.	0.8	1
112	Conventional external beam volumes for cervical cancer: Are they adequate?. South Asian Journal of Cancer, 2013, 2, 126.	0.2	1
113	Ten years and counting: Survival in stage IV metastatic squamous cell carcinoma of anal canal following radical treatment. Journal of Cancer Research and Therapeutics, 2020, 16, 227.	0.3	1
114	A simple cost-effective modification improves the quality of immunocytochemical staining in cervical scrape samples characterized by presence of excess mucus. Journal of Histotechnology, 2014, 37, 3-8.	0.2	0
115	Adjuvant Therapy in Endometrial Cancer with Special Emphasis and Reference to Indian Setting. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	0
116	Response to Yuce Sari et al.. Radiotherapy and Oncology, 2021, 158, 323-324.	0.3	0
117	Paraortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18â€“Fluorodeoxyglucose PET (Positron Emission Tomography) in Advanced Cervical Cancer: Final Results of a Prospective Observational Cohort Study. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	0
118	Cross-sectional Analysis of Quality of Life in Long-Term Survivors of Carcinoma Cervix Treated with Chemoradiation/Neo-Adjuvant Chemotherapy Followed by Surgery. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	0
119	Treatment Compliance and Clinical Outcomes in Older Patients with Cervical Cancer Treated with Radio(chemo)therapyâ€“A Retrospective Analysis. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	0
120	Reply to the comments on â€œSetup error analysis in helical tomotherapy based image-guided radiation therapy treatmentsâ€“by Slav Yartsev. Journal of Medical Physics, 2016, 41, 72.	0.1	0
121	Pigmented Villonodular Synovitis: A Close Mimic of Metastasis on F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Indian Journal of Nuclear Medicine, 2018, 33, 82-83.	0.1	0
122	Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series. Journal of Contemporary Brachytherapy, 2021, 13, 649-654.	0.4	0